Home Drug Codes C Codes C9307 · LYNOZYFIC
Updated July 1st, 2026

LYNOZYFIC C Code: C9307

Injection, linvoseltamab-gcpt, 1 mg

Login to unlock all benchmarks
Medicare Payment Limit ?
Not published
CMS publishes none for Q3 2026
APC Payment Limit ?
Not published
CMS publishes none for Q3 2026
ASP ?
No current ASP
Not available for Q3 2026
WAC · AWP ?
$•••.••
Login to view
NDCs Crosswalked ?
2
View NDC crosswalk →

Drug & Product Overview

HCPCS Descriptor Injection, linvoseltamab-gcpt, 1 mg
HCPCS Added Date January 1, 2026
Manufacturer Regeneron Pharmaceuticals, Inc
Route of Administration Intravenous
Generic Status HCPCS Discontinued
Dosage Type Single-Dose
Dosage Form Injection, Solution, Concentrate

About LYNOZYFIC

Lynozyfic is a medication aligned to the HCPCS C Code: C9307 for billing, pricing, and reimbursement purposes in the United States. This Oncology medication is administered via the intravenous route and manufactured by Regeneron Pharmaceuticals, Inc.

Manufacturers, reach out to us to add more information.

NDC Code Information

2 NDC packages are crosswalked to C9307. Package detail is available to logged-in subscribers.

Login to view 2 NDC packages View pricing, complete NDC-to-HCPCS alignments, and package details.
Login →

LYNOZYFIC CPT Administration Codes

The below list of CPT codes is intended for informational purposes only and may not be exhaustive. CPT® codes and descriptions are copyright American Medical Association (AMA). All rights reserved.

CPT Code Description
96413 Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
96415 Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)
Not on the CMS JW / JZ list

This product is new and does not yet appear on the CMS list of HCPCS pertaining to single-dose containers. Wastage billing guide →

LYNOZYFIC Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

relapsed or refractory multiple myeloma

Login for BuyandBill.com Analytics

Unlock deeper insights with BuyandBill’s Comparative Report!

  • Compare ASP, WAC, and AWP across drugs.
  • Visualize Drug Price Movement Over Time
  • Tailor reports to drug class, manufacturer, or HCPCS Code.
  • Compare Biosimilar and 505(b)(2) products.

Frequently Asked Questions

Is there a manufacturer-published LYNOZYFIC billing and coding guide?
Our team has not identified a manufacturer-published source of billing and coding information for LYNOZYFIC.
Is there an available LYNOZYFIC patient assistance program?
Our team has not identified a manufacturer-published source of patient assistance information for LYNOZYFIC.
Where can I find LYNOZYFIC prescribing information?
LYNOZYFIC prescribing information can be found at the link below. Visit Here →
Where can I find LYNOZYFIC side effect information?
LYNOZYFIC side effect information can be found through MedlinePlus. Visit Here →
Does billing LYNOZYFIC require JZ/JW wastage modifiers?
CMS does not include LYNOZYFIC (C9307) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing C9307. For more information, visit the link below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.